Lanean...
Emerging treatments in Castleman disease – a critical appraisal of siltuximab
Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of CD is fueled by excessive interleukin-6 (IL-6) has led to considerable interest in therapeutic targeting of this cytokine. Siltuximab, a c...
Gorde:
| Argitaratua izan da: | Biologics |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734738/ https://ncbi.nlm.nih.gov/pubmed/26869762 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S60523 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|